📌 Is HIMS a Buy right now?
According to Ultra Stock Analysis Pro, Hims & Hers Health, Inc. (HIMS) is currently rated WAIT (Signal Strength: 0/7). The long-term fundamentals are stable (P/E: 18.4, Revenue Growth: +3.8%), while short-term technicals show a bullish trend (RSI: 48). Consider waiting for support confirmation near $31.47 before adding exposure.
For the latest stock analysis and interactive charts:
📊 Open HIMS Analysis ↗
Why this rating?
The Ultra Stock Analysis algorithm has assigned a WAIT rating to HIMS based on a confluence of 3 distinct factors:
📊 Confidence Interval:
Based on 7+ years of historical data, signals with this specific technical fingerprint have resulted in a positive return 81% of the time over a medium-term (months) hold period, with an average return of +26.6% per trade.
To assist with risk management, here are the three most probable paths for HIMS over the next trading week:
🟢 The Bull Case (Probability: 20%)
If HIMS reclaims the $31.47 resistance level (Bollinger Upper), algorithmic targets shift to $31.47. This move would likely be driven by continued sector rotation into Healthcare.
🔴 The Bear Case (Probability: 50%)
Failure to hold the $23.40 support zone (Bollinger Lower) triggers a defensive stop-loss signal. In this scenario, the algorithm projects a slide toward the $21.28 liquidity zone (-15.0% from current price).
🟡 The Base Case (Sideways)
Given the current ADX of 25 (strong trend), momentum suggests a directional move is imminent between $23.40 and $31.47 until a volume catalyst occurs.
⚠️ These scenarios are algorithm-generated projections based on technical analysis, not financial advice. Past performance does not guarantee future results.
| TECHNICAL METRICS | VALUE | FUNDAMENTAL METRICS | VALUE |
|---|---|---|---|
| Current Price | $25.05 | Market Cap | $5.8B |
| Past Win Rate (Backtest) | 81.2% | Forward P/E | 18.4x |
| Past Total Return | +100.0% | Analyst Target | $26.82 |
| RSI / Trend Strength | 48 / 25 | Upside to Target | +7.1% |
| MACD Signal | Bullish | Revenue Growth | +3.8% |
| Profit Factor | 2.36 | Institutional Own. | 68.6% |
| Position Entry | 2026-04-21 @ $29.76 | Analyst Ratings | 3 Buy / 10 Hold / 2 Sell |
| Open Position Past P&L | -15.8% |
MAINTAIN POSITION - Current position showing -15.8% unrealized gain. Use intelligent stop loss strategy below.
Both strategies analyzed independently. Conservative uses fixed 2.0x ATR stops. Hybrid adapts stops based on position profit (tighter as profit grows).
Fixed 2.0x ATR Stop Loss
Entry: $29.76 on 2026-04-21
Confluence: nan
Stop Loss: $20.80
Backtest Results (Since 2018):
Past Win Rate
81%
Past Total Return
+100.0%
Max Drawdown
-88.2%
Avg Trade
+26.6%
Trades
16
Adaptive ATR Stop Loss (1.0-2.75x)
Entry: $29.76 on 2026-04-21
Confluence: nan
Stop Loss: $21.87
Backtest Results (Since 2018):
Past Win Rate
81%
Past Total Return
+136.4%
Max Drawdown
-88.2%
Avg Trade
+31.2%
Trades
16
Current Price
$25.05
Buy Stop Loss
$20.80
Distance: 17%
Conservative 2.0x
Position Stop Loss
$19.21
Distance: 23%
Hybrid 2.75x
ATR 14 Day
$2.12
Volatility
ADX Strength
25.4
Strong trend
Position down -16% - Wider stops for recovery
ADX: 20-25 = Emerging trend | 25-50 = Strong trend | 50+ = Very strong
| Indicator | Value | Signal |
|---|---|---|
| EMA 20 | $25.99 | Bearish |
| EMA 50 | $25.11 | Bearish |
| RSI (14) | 48.0 | Neutral range |
| Trend Strength (ADX) | 25.4 | Strong trend (25-50) |
Recent upgrades, downgrades, and price target changes (last 90 days)
| Firm | Action | From → To | Date |
|---|---|---|---|
| BTIG | REITERATED | Neutral → Neutral | May 12, 2026 |
| JP Morgan | INITIATED | Overweight | Apr 24, 2026 |
| Citigroup | UPGRADE | Sell → Neutral | Mar 10, 2026 |
| B of A Securities | UPGRADE | Underperform → Neutral | Mar 10, 2026 |
| Needham | UPGRADE | Hold → Buy | Mar 09, 2026 |
| BTIG | DOWNGRADE | Buy → Neutral | Feb 24, 2026 |
| Truist Securities | REITERATED | Hold → Hold | Feb 24, 2026 |
| Average Target: | $26.82 | High Target: | $35.00 |
| Current Price: | $25.05 | Low Target: | $18.00 |
| Upside to Average: | +7.1% | Number of Analysts: | 14 |
Based on backtest performance (Win Rate: 81.2%, Avg Return: +26.6%) and analyst consensus (Target: $26.82, +7.1% upside), a MARKET WEIGHT exposure may be considered. Risk/Reward ratio of 0.47:1 suggests unfavorable risk-adjusted returns. Current open position shows -15.8% unrealized gain.
Hims & Hers Health, Inc. operates in the Healthcare sector (Drug Manufacturers - Specialty & Generic). Current valuation of 18.4x forward P/E reflects reasonable multiples relative to growth prospects. Operating margin of -7.9% shows compressed profitability.
Fundamental Outlook: Neutral - Mixed signals with focus on execution and margin improvement
Overall Score: 2.7/10 - Slightly Bullish
DOCS vs. HIMS: Which Stock Is the Better Value Option?...
Telehealth company Hims & Hers Health (NYSE:HIMS) fell short of the market’s revenue expectations in Q1 CY2026 as sales rose 3.8% year on year to $608...
Recently, Zacks.com users have been paying close attention to Hims & Hers Health (HIMS). This makes it worthwhile to examine what the stock has in sto...
The stock continues to be very volatile....
The news sentiment is moderately bullish, showing generally positive coverage with some caution. Market perception appears favorable but not overwhelmingly positive. This neutral-to-positive sentiment suggests steady conditions without extreme optimism.
| Metric | Value |
|---|---|
| Market Cap | $5.8B |
| P/E Ratio (Forward) | 18.4 |
| EPS (Forward) | $1.36 |
| Dividend Yield | 0.00% |
| 52-Week Range | $13.74 - $70.43 |
| Beta | 2.42 |
| Avg Volume | 35.9M |
Comprehensive Technical Data for Quantitative Analysis
| Indicator | Value | Indicator | Value |
|---|---|---|---|
| Close Price | $25.05 | Volume | 20.6M |
| EMA 20 | $25.99 | EMA 50 | $25.11 |
| EMA 200 | $31.38 | Current Price | $25.05 |
| RSI (14) | 48.04 | MACD | 0.304 |
| MACD Signal | 0.894 | MACD Histogram | -0.591 |
| Trend Strength (ADX) | 25.40 | Volatility (ATR 14) | $2.12 |
| Bollinger Upper | $31.47 | Bollinger Lower | $23.40 |
| Stochastic %K | 16.39 | Stochastic %D | 17.78 |
| VWAP | $24.63 | Bollinger Middle | $27.43 |
| Confluence Score | 0/7 | Trade Signal | NONE |
Comprehensive Fundamental Data for Financial Analysis
| Valuation Metrics | Performance | ||
|---|---|---|---|
| Market Cap | $5.8B | Revenue | $2.4B |
| Forward P/E | 18.4 | Revenue Growth | +3.8% |
| Trailing P/E | 0.0 | Gross Margin | 72.9% |
| Price/Sales | 2.45 | Operating Margin | -7.9% |
| Price/Book | 10.53 | Profit Margin | -0.6% |
| PEG Ratio | 2.15 | ROE | -2.7% |
| Enterprise Value | $6.2B | Free Cash Flow | $0.2B |
Comprehensive Trading Performance and Position Details
| Entry Date | Entry Price | Past P&L | Entry Stop Loss |
|---|---|---|---|
| 2026-04-21 | $29.76 | -15.83% | $25.49 |
| Entry Date | Exit Date | Entry Price | Exit Price | Return % | Result |
|---|---|---|---|---|---|
| 2022-10-19 | 2022-11-09 | $4.09 | $5.52 | +34.96% | Win |
| 2022-11-17 | 2023-05-26 | $5.82 | $9.07 | +55.84% | Win |
| 2023-11-15 | 2024-05-03 | $7.71 | $11.26 | +46.04% | Win |
| 2024-05-16 | 2024-06-18 | $14.04 | $24.79 | +76.57% | Win |
| 2024-10-04 | 2025-03-20 | $17.66 | $32.87 | +86.13% | Win |
| 2025-05-05 | 2025-06-03 | $41.88 | $54.73 | +30.68% | Win |
| 2025-06-23 | 2025-08-18 | $41.98 | $45.10 | +7.43% | Win |
| 2025-09-18 | 2025-10-28 | $56.20 | $47.12 | -16.16% | Loss |
| 2026-01-12 | 2026-02-05 | $32.34 | $23.48 | -27.40% | Loss |
| 2026-04-16 | 2026-04-17 | $26.99 | $28.82 | +6.78% | Win |
Summary: 16 total trades | Strategy: Conservative Stop Loss (Fixed ATR-based)
Disclaimer: This report is for informational and educational purposes only and does not constitute investment advice. Ultra Stock Analysis Pro is not a registered investment advisor; information is impersonal and not tailored to individual circumstances. AI-generated content may contain errors — verify before acting. Past performance is not indicative of future results. Technical analysis based on historical data through 2026-05-15. Fundamental data auto-fetched from Yahoo Finance. Please conduct your own due diligence before making investment decisions.
Report Generated: May 16, 2026 at 12:18 PM
Ultra Stock Analysis Pro - Comprehensive Technical & Fundamental Analysis